Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04162769




Registration number
NCT04162769
Ethics application status
Date submitted
12/11/2019
Date registered
14/11/2019
Date last updated
4/11/2022

Titles & IDs
Public title
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
Scientific title
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (With a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
Secondary ID [1] 0 0
APD334-201
Universal Trial Number (UTN)
Trial acronym
ADVISE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Etrasimod 1 mg
Treatment: Drugs - Etrasimod 2 mg
Treatment: Drugs - Etrasimod matching placebo

Experimental: 12-Week Double-Blind Treatment Period: Etrasimod 1 milligrams (mg) -

Experimental: 12-Week Double-Blind Treatment Period: Etrasimod 2 mg -

Placebo Comparator: 12-Week Double-Blind Treatment Period: Placebo -

Experimental: 52-Week Open-Label Extension Period: Etrasimod 2 mg -


Treatment: Drugs: Etrasimod 1 mg
Etrasimod 1 mg tablet taken by mouth, once daily

Treatment: Drugs: Etrasimod 2 mg
Etrasimod 2 mg tablet taken by mouth, once daily.

Treatment: Drugs: Etrasimod matching placebo
Etrasimod matching placebo tablet by mouth, once daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score
Timepoint [1] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [1] 0 0
Double-blind Treatment Period: Percentage of Participants Achieving EASI-75
Timepoint [1] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [2] 0 0
Double-blind Treatment Period: Percentage of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of >= 2 Points
Timepoint [2] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [3] 0 0
Double-blind Treatment Period: Percent Change in Weekly Peak Pruritus Numerical Rating Scale (NRS) From an Itch Daily Diary
Timepoint [3] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [4] 0 0
Double-blind Treatment Period: Percentage of Participants With Improvement (Reduction) in Peak Pruritus NRS Greater Than or Equal to (>=)3 From an Itch Daily Diary
Timepoint [4] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [5] 0 0
Double-blind Treatment Period: Percentage of Participants Achieving EASI-50
Timepoint [5] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [6] 0 0
Double-blind Treatment Period: Percentage of Participants Achieving EASI-90
Timepoint [6] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [7] 0 0
Double-blind Treatment Period: Percent Change in Percent Body Surface Area (BSA)
Timepoint [7] 0 0
Baseline (Day 1) and Week 12
Secondary outcome [8] 0 0
Open-label Extension (OLE) Period: Percent Change in EASI
Timepoint [8] 0 0
Baseline (Week 16) and Week 68
Secondary outcome [9] 0 0
OLE Period: Number of Participants Achieving a EASI-75 Score
Timepoint [9] 0 0
Baseline (Week 16) and Week 68
Secondary outcome [10] 0 0
OLE Period: Number of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of = 2 Points
Timepoint [10] 0 0
Baseline (Week 16) and Week 68
Secondary outcome [11] 0 0
OLE Period: Percent Change in SCORing Atopic Dermatitis (SCORAD) Total Score
Timepoint [11] 0 0
Baseline (Week 16) and Week 68
Secondary outcome [12] 0 0
OLE Period: Percent Change in Percent BSA
Timepoint [12] 0 0
Baseline (Week 16) and Week 68
Secondary outcome [13] 0 0
OLE Period: Percent Change in Weekly Peak Pruritus NRS From an Itch Daily Diary
Timepoint [13] 0 0
Baseline (Week 16) and Week 28
Secondary outcome [14] 0 0
OLE Period: Change in Patient-Oriented Eczema Measure (POEM)
Timepoint [14] 0 0
Baseline (Week 16) and Week 68
Secondary outcome [15] 0 0
OLE Period: Change in Dermatology Life Quality Index (DLQI)
Timepoint [15] 0 0
Baseline (Week 16) and Week 68
Secondary outcome [16] 0 0
OLE Period: Change in Patient Global Assessment (PGA) of Disease
Timepoint [16] 0 0
Baseline (Week 16) and Week 68

Eligibility
Key inclusion criteria
Inclusion criteria:

- Participants with chronic atopic dermatitis, defined by Hanifin and Rajka criteria,
that has been present for at least 1 year prior to the Screening Visit

- Participants with Eczema Area and Severity Index (EASI) = 12 at the Screening Visit
and = 16 at the Baseline Visit

- Participants with validated Investigator's Global Assessment (vIGA) score = 3 (on the
0 to 4 vIGA scale, in which 3 = moderate and 4 = severe) involvement at the Screening
and Baseline visits
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Presence of skin comorbidities that would interfere with study assessments of the
underlying disease.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/10/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/10/2021
Sample size
Target
Accrual to date
Final
140
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Premier Specialists PTY LTD - Kogarah
Recruitment hospital [2] 0 0
Sinclair Dermatology - East Melbourne
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Mississippi
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
South Dakota
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Virginia
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Arena Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment
for moderate-to-severe atopic dermatitis (AD).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04162769
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Arena CT.gov Administrator
Address 0 0
Arena Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries